Medically reviewed by Drugs.com. Last updated on May 5, 2020.
(moe MET a sone)
- Mometasone Furoate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Cream, External, as furoate:
Elocon: 0.1% (15 g [DSC], 50 g [DSC]) [contains soybean lecithin]
Generic: 0.1% (15 g, 45 g)
Ointment, External, as furoate:
Elocon: 0.1% (15 g [DSC], 45 g [DSC]) [contains propylene glycol stearate]
Generic: 0.1% (15 g, 45 g)
Solution, External, as furoate:
Generic: 0.1% (30 mL, 60 mL)
Brand Names: U.S.
- Elocon [DSC]
- Corticosteroid, Topical
Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Mometasone has intermediate range potency.
Cream: 0.4% (increased by inflammation)
Lotion, ointment, solution: 0.7% (increased by inflammation)
Use: Labeled Indications
Corticosteroid-responsive dermatoses: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid)
Hypersensitivity to mometasone furoate or any component of the formulation.
Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Canadian labeling: Additional contraindications (not in US labeling): viral (eg, herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations, acne vulgaris, rosacea, pruritus without inflammation; ophthalmic use; use with occlusive dressings
Corticosteroid-responsive dermatoses: Topical: Apply sparingly, do not use occlusive dressings. Therapy should be discontinued when control is achieved; consider reassessment of diagnosis if no improvement is seen within 2 weeks.
Cream, ointment: Apply a thin film to affected area once daily
Lotion, solution: Apply a few drops to affected area once daily
Refer to adult dosing. Use with caution as elderly patients may be more susceptible to systemic effects.
Note: Discontinue therapy when control is achieved; reassess diagnosis if no improvement is seen in 2 weeks
Cream, ointment: Children ≥2 years and Adolescents: Topical: Apply a thin film to affected area once daily; do not use in pediatric patients for >3 weeks
Lotion, solution: Children ≥12 years and Adolescents: Topical: Apply a few drops to affected area once daily; massage lightly into skin
Apply sparingly. Avoid mucous membranes; manufacturer labeling recommends avoiding application to the eyes, face, underarms, and groin (including diaper area). Do not wrap, cover, or bandage affected area.
Cream, ointment: Apply thin film to affected area.
Lotion, solution: Apply a few drops to affected area and massage lightly until medication disappears.
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination
1% to 10%:
Central nervous system: Paresthesia (lotion, infants & children: ≤3%, cream, children: 1%)
Dermatologic: Dyschromia (loss of normal skin markings: ≤6%), taut and shiny skin (≤6%), folliculitis (lotion: 3%; cream, children: <1%), telangiectasia (≤3%), dermatologic disorders (2%), bacterial skin infection (infants & children: ≤2%), epidermal thinning (≤2%)
Endocrine & metabolic: Decreased cortisol (infants & children: lotion: ≤6%, cream and ointment: ≤2%), endocrine disease (lotion: 2%)
Gastrointestinal: Xerostomia (infants & children: 2%)
Hematologic & oncologic: Bruise (1%)
Local: Application site burning (2%), application site pruritus (≤2%)
Frequency not defined:
Central nervous system: Tingling of skin
Dermatologic: Acne rosacea, furunculosis, skin atrophy, stinging of the skin (application site)
<1%, postmarketing, and/or case reports: Acneiform eruption, cataract, cutaneous candidiasis, glaucoma, skin depigmentation
Concerns related to adverse effects:
• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.
•Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.
• Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.
• Ocular effects: Topical corticosteroids, including mometasone, may increase the risk of posterior subcapsular cataracts and glaucoma. Monitor for ocular changes. Avoid contact with eyes.
• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.
• Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.
• Pediatric: Not for treatment of diaper dermatitis. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.
Dosage form specific issues:
• Appropriate use: Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions.
Adrenal suppression with extensive/prolonged use (ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); response to treatment; ocular changes
Pregnancy Risk Factor
Adverse events have been observed in animal reproduction studies.
Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth weight infants following maternal use of potent or very potent topical products, especially in high doses. Use of mild to moderate potency topical corticosteroids is preferred in pregnant females and the use of large amounts or use for prolonged periods of time should be avoided (Chi 2016; Chi 2017; Murase 2014). Also avoid areas of high percutaneous absorption (Chi 2017). The risk of stretch marks may be increased with use of topical corticosteroids (Murase 2014).
What is this drug used for?
• It is used to treat skin irritation.
• It is used to treat skin rashes.
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• High blood sugar like confusion, feeling sleepy, more thirst, hunger, passing urine more often, flushing, fast breathing, or breath that smells like fruit
• Skin changes like pimples, stretch marks, slow healing, or hair growth
• Severe skin irritation
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about mometasone topical
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 73 Reviews
- Drug class: topical steroids
- Mometasone Furoate topical (AHFS Monograph)
- Mometasone Cream (FDA)
- Mometasone Lotion (FDA)
- Mometasone Ointment (FDA)
Other brands: Elocon